New strategies are needed in diffuse malignant mesothelioma
Authors:
- William A. RaubWRWilliam A. Raub
Open Access
- 15 December 1992
- Vol. 70 (12) , 2969-2979
Abstract
Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were abstracted and analyzed by statistical software. Results. The male-to-female ratio was 4:l. The age distribution was younger than 45 years of age, 10%; 45–54 years of age, 12%; 55–64 years of age, 37%; 65–74 years of age, 33%; and 75 years of age or older, 8%. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73%; peritoneum, 20%; and both, 6%. The histologic types were epithelial, 51%; sarcomatous, 10%; mixed, 15%; and not specified, 24%. The stage at presentation was Stage I, 37%; 11, 39%; 111, 12%; IV, 6%; and unknown, 6%. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0–23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13,10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier-stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratifization into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multi technique trials incorporating primary Chemotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Clinical Features of Adenosquamous Lung Carcinoma in 127 PatientsAmerican Review of Respiratory Disease, 1990
- Activity of pirarubicin (4′-o-tetrahydropyranyladriamycin) in malignant mesotheliomaCancer, 1989
- Prognostic Factors in Diffuse Malignant Pleural MesotheliomaChest, 1988
- Pleural Neoplasms1988
- New marker for mesothelioma: an immunoperoxidase study.Journal of Clinical Pathology, 1986
- Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experienceCancer, 1983
- Diffuse Malignant MesotheliomaAnnals of Internal Medicine, 1982
- Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.Thorax, 1976
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958